At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Apr 15, 2026 at 08:30 ET
Xenon Pharmaceuticals reported a Q4 2025 EPS miss of -9.4% versus consensus, with actual EPS at $-1.31 compared to an estimated $-1.20. The press release contains no financial results or operational updates, only investor conference announcements.
- Reported EPS of $-1.31 missed consensus estimate of $-1.20 by 9.4%, indicating worsening losses.
- No revenue or operating metrics were disclosed in the release; only investor event schedule was provided.
- Company announced upcoming presentations at four investor conferences in Q2 2026, but no new clinical or financial data.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access